## Brief alcohol interventions in the breast screening setting: are they needed, are they acceptable and do they work?

Jasmin Grigg<sup>1,2</sup>, Victoria Manning<sup>1,2</sup>, Peta Stragalinos<sup>1,2</sup>, Christopher J Greenwood<sup>3,4</sup>, Ali Cheetham<sup>1,2</sup>, Chloe Bernard<sup>1,2</sup>, Isabelle Volpe<sup>1,2</sup>, Darren Lockie<sup>5</sup>, Michelle Giles<sup>5</sup>, Robin Bell<sup>6</sup>, Liam Smith<sup>7</sup>, Peter Bragge<sup>7</sup>, Dan I Lubman<sup>1,2</sup>

<sup>1</sup>Turning Point, Eastern Health, Melbourne, Australia <sup>2</sup>Monash Addiction Research Centre, Eastern Health Clinical School, Monash University, Melbourne, Australia <sup>3</sup>School of Psychology, Deakin University, Geelong, Australia <sup>4</sup>Centre for Adolescent Health, Murdoch Children's Research Institute, Melbourne, Australia <sup>5</sup>Maroondah BreastScreen, Eastern Health, Melbourne, Australia <sup>6</sup>School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia, <sup>7</sup>BehaviourWorks Australia, Monash Sustainable Development Institute, Monash University, Melbourne, Australia

Presenter's email: jasmin.grigg@monash.edu

**Introduction:** Alcohol is a major modifiable breast cancer risk factor, even in very low amounts. Yet, awareness of this risk remains low, including among midlife and older-aged women who are drinking at increasingly risky levels. Informed by our mixed-methods pre-implementation research with breast screening service consumers (demonstrating need and acceptability), we developed and examined the effectiveness of a brief alcohol intervention for improving awareness of alcohol as a breast cancer risk factor, improving alcohol literacy, and reducing alcohol consumption among women attending routine breast screening.

**Method:** This double-blind randomised controlled trial recruited women attending Maroondah BreastScreen (Eastern Health, Melbourne) between February-August 2021, reporting any level of alcohol consumption. The active arm comprised brief alcohol and lifestyle intervention. The control arm comprised brief lifestyle intervention only. Interventions were delivered via animation on an iPad.

**Results:** Of 557 participants, mean age was 60.3 years (SD=7.7, range 40-87 years), 455 (81.7%) had recently consumed alcohol, and 110 (19.8%) were aware of the alcohol-breast cancer link. There were significant increases in the proportion of participants identifying alcohol as a breast cancer risk factor at four weeks for active (65.4%v19.8%, OR=41.3, 95% CI 17.6–97.0) and control (37.8%v19.7%, OR=4.9, 95% CI 2.8–8.8) arms, with change over time greater for the active arm ( $p_{arm \times time} < 0.001$ ). Alcohol literacy also increased to a greater extent in the active arm. Change in alcohol consumption was not observed.

**Discussion/Conclusion:** This is the first study to demonstrate the benefits of a tailored brief alcohol intervention implemented in the breast screening setting.

**Practice/Policy Implications:** Alcohol brief interventions in this novel clinical setting reach a population previously overlooked as a target of alcohol health promotion, have huge potential for scalability, and are particularly relevant given this group's rising prevalence of risky drinking, and evidence that even very low consumption increases breast cancer risk.

**Disclosure of Interest Statement:** This work was supported by research grants from VicHealth and the Eastern Health Foundation. The funders had no role in any part of this study. DIL, VM, RB and JG have received grants from the National Health and Medical Research Council. DIL, VM and RB have received grants from the Medical Research Future Fund. DIL, VM and JG have received funding from Shades of Pink and the Victorian Department of Health. DIL and VM have received grants from the HCF Research Foundation, the Alcohol and Drug Research Innovation Agenda, the Alcohol and Drug Foundation, the Eastern Health Foundation, the Victorian Responsible Gambling

Foundation, and the National Centre for Clinical Research on Emerging Drugs. DIL has received grants from Google, the Australian Research Council, VicHealth, and the Australian Department of Health and Aged Care. VM has received funding from the Transport Accident Commission (Victoria). JG has received funding from the Victorian Department of Transport and Planning. DIL is supported by a National Health and Medical Research Council Leadership Fellowship. IV is supported by an Australian Government Research Training Program stipend.